|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent RMED insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why RMED insider buys are important for investors to follow.
Date | Insider | Price | Amount |
8-3-2020 Insider Buy |
Jonathan Will McGuire Chief Executive Officer |
$0.35
CAGR »
|
$3,500.00 10,000 shares |
11-19-2020 Insider Buy |
Richard Mejia Jr. Director |
$5.82
CAGR »
|
$5,820.00 1,000 shares |
11-19-2020 Insider Buy |
William R. Enquist Director |
$5.82
CAGR »
|
$30,621.71 5,263 shares |
11-19-2020 Insider Buy |
Martin J. Colombatto Director |
$5.78
CAGR »
|
$50,279.04 8,700 shares |
11-19-2020 Insider Buy |
Joan Stafslien Director |
$5.67
CAGR »
|
$25,002.49 4,410 shares |
8-3-2020 Insider Buy |
Daniel Horwood General Counsel |
$0.35
CAGR »
|
$3,500.00 10,000 shares |
8-3-2020 Insider Buy |
Andrew C. Jackson CFO |
$0.35
CAGR »
|
$3,500.00 10,000 shares |
8-3-2020 Insider Buy |
Jeffrey J. Kraws Co-President |
$0.35
CAGR »
|
$3,500.00 10,000 shares |
6-12-2020 Insider Buy |
Richard Mejia Jr. Director |
$0.60
CAGR »
|
$29,915.00 50,000 shares |
5-29-2020 Insider Buy |
William R. Enquist Director |
$0.47
CAGR »
|
$23,700.00 50,000 shares |
5-22-2020 Insider Buy |
Andrew C. Jackson CFO |
$0.46
CAGR »
|
$4,648.00 10,000 shares |
5-22-2020 Insider Buy |
Jeffrey J. Kraws Co-President |
$0.46
CAGR »
|
$4,600.00 10,000 shares |
5-22-2020 Insider Buy |
Daniel Horwood General Counsel |
$0.47
CAGR »
|
$4,650.00 10,000 shares |
5-22-2020 Insider Buy |
Jonathan Will McGuire Chief Executive Officer |
$0.46
CAGR »
|
$4,648.00 10,000 shares |
Also See: Institutional Holders of RMED
Also See: SEC filings
Below we present the annualized performance delivered by RMED stock since 8-3-2020 (the date of the most recent
insider purchase). The performance of the investment from the time RMED insider buying occurred is the ultimate
test of whether insiders were right about RMED being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
08/04/2020 |
|
End date: |
08/17/2023 |
|
Start price/share: |
$375.00 |
|
End price/share: |
$0.59 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.84% |
|
Average Annual Total Return: |
-88.07% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$15.74 |
|
Years: |
3.04 |
|
RMED Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent RMED insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding RMED
|
|